Curocell

372320 · KQ · Healthcare / Biotechnology

22,300.00KRW-450.00 (-1.98%)

Price History

Full chart

Market Stats

Previous Close22,750.00

Open22,700.00

Day Range22,200.00 – 23,450.00

52-Week Range20,650.00 – 66,000.00

Volume15.94K

Market Cap350.20B

P/E (TTM)0.00

Forward P/E0.00

Dividend Yield0.00%

Beta0.77

50-Day Avg23,714.00

200-Day Avg39,085.25

About

Curocell Inc., a cell gene therapy development company, engages in the development and manufacturing of pharmaceuticals. It provides research and development services; and OVercome Immune Suppression (OVIS), a proprietary platform technology designed to get away from exhaustion induced by immune checkpoint receptors. The company is also involved in the development of CD19 CAR-T treatment, blood cancer CAR-T, solid cancer CAR-T, and allogeneic CAR-T. Curocell Inc. was founded in 2016 and is headquartered in Daejeon, South Korea.

Company Details

SectorHealthcare
IndustryBiotechnology
CEOMr. Kim Gunsoo
Employees136
Headquarters11 Gukje Science 16-ro, Daejeon, South Korea, 34002, Korea
Websitehttps://www.curocellbtx.com

Leadership

Mr. Kim GunsooCo-founder & CEO
Hyunbo SimCo-Founder
Chanhyeok KimCo-Founder
Mr. Park Jin KyongCFO, Executive Director & Senior MD
Mr. Tae Hyun KimSenior Director & Chief Human Officer
Mr. Jeon Dong HyukSenior Director & Head of Production Engineering Center
Mr. Kim Hyung Cheol Ph.D.Executive VP, Head of R&D Center and Director

Financials

Income Statement

Currency: KRW	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Revenue	-	0	0	0	-
Cost of Revenue	-	0	0	0	-
Gross Profit	-	0	0	0	-
Operating Expense	-	21.42B	31.13B	36.62B	-
Operating Income	-15.29B	-21.42B	-31.13B	-36.62B	-36.29B
EBITDA	-	-36.85B	-22.53B	-29.30B	-35.64B
Net Income	-53.58B	-38.89B	-29.57B	-38.24B	-46.31B
R&D	13.16B	19.67B	27.19B	31.86B	31.25B
Interest Expense	195.18M	207.32M	2.43B	2.60B	4.54B

Balance Sheet

Currency: KRW	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Assets	82.16B	87.99B	104.97B	72.02B	109.72B
Total Liabilities	94.40B	135.59B	45.87B	42.57B	104.70B
Total Equity	-12.24B	-47.60B	59.10B	29.45B	5.03B
Cash	42.59B	6.63B	9.92B	4.58B	10.16B
Net Debt	-	19.46B	30.48B	30.61B	44.60B

Cash Flow

Currency: KRW	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Operating Cash Flow	-11.54B	-14.39B	-25.26B	-28.42B	-29.99B
Investing Cash Flow	-	-40.72B	-21.13B	22.02B	-
Financing Cash Flow	-	19.15B	49.68B	1.04B	-
Capital Expenditure	9.30B	27.87B	21.65B	1.21B	2.22B
Free Cash Flow	-20.84B	-42.26B	-46.91B	-29.63B	-32.21B
FCF to OCF	180.61%	293.65%	185.70%	104.26%	107.39%

Earnings

Report Date	Dec 31, 2023	Mar 31, 2024	Jun 30, 2024	Sep 30, 2024	Dec 31, 2024	Mar 31, 2025	Jun 30, 2025	Sep 30, 2025	Dec 31, 2025	Mar 31, 2026	Jun 30, 2026
EPS Estimate	-	-	-	-	-	-	-	-	-	-	-
EPS Actual	-631.30	-2813.00	-554.43	-738.77	-738.21	-477.41	-822.34	-711.95	-1218.90	-590.71	-1160.51
Surprise	-	-	-	-	-	-	-	-	-	-	-
Timing	-	-	-	-	-	-	-	-	-	-	-

Key Statistics & Ratios

Market Cap350.20B

Enterprise Value300.75B

Trailing P/E0.00

Forward P/E0.00

Price / Sales0.00

Price / Book4.47

Revenue (TTM)0

Gross Profit (TTM)-2.68B

EBITDA-29.08B

Profit Margin0.00%

Operating Margin0.00%

Return on Equity-101.11%

Return on Assets-16.04%

Shares Outstanding15.23M

Shares Float9.85M

Beta0.77

Dividend Yield0.00%

Dividend Rate0.00

Payout Ratio0.00%